Skip to main content
. 2022 Aug 15;2(8):806–813. doi: 10.1158/2767-9764.CRC-21-0143

FIGURE 1.

FIGURE 1

Best overall response. A, ORR data for all patients and by disease category for patients treated with either ICI monotherapy or chemo/ICI combination therapy. B, ORR data for all patients and by disease category for patients treated with ICI monotherapy. C, ORR data for patients with NSCLC stratified by PD-L1 status treated with ICI monotherapy. Only patients for whom PD-L1 was known were included.